PF-06465469

PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma[1][2].

Product Specifications

CAS Number

[1407966-77-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H413

Target

Btk; CXCR; Itk; LAG-3; PD-1/PD-L1

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pf-06465469.html

Purity

99.48

Solubility

DMSO : 11 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C(C)C)C(C)=C1)C2=CC=CC(C3=NN([C@H]4CN(C(C=C)=O)CCC4)C5=NC=NC(N)=C53)=C2

Molecular Formula

C30H33N7O2

Molecular Weight

523.63

Precautions

H315, H319, H335, H413

References & Citations

[1]Mamand S, et al. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. Sci Rep. 2018 Sep 21;8 (1) :14216.|[2]Fu Z, et al. IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells. J Clin Invest. 2024 Nov 26;135 (4) :e178558.